Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natsuki Hori

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 23, 2008
[Urological oncology emergencies]Natsuki Hori, Masahiro Suzuki
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 9, 2005
[Pain management for cancer patients with critical pathway on computer]Natsuki Hori, Toshiro Konishi
Atherosclerosis|February 8, 2011
Calpain-mediated cleavage negatively regulates the expression level of ABCG1Natsuki Hori, Hisamitsu Hayashi, Yuichi Sugiyama
Nutrients|November 27, 2021
Association of Lifestyle Changes Due to the COVID-19 Pandemic with Nutrient Intake and Physical Activity Levels during Pregnancy in JapanNatsuki Hori, Mie Shiraishi, Rio Harada, et al.
Nutrients|February 11, 2023
Psychosocial Experiences Related to Dietary Behavior of Japanese Lactating Women: A Qualitative StudyKaori Matsuda, Mie Shiraishi, Natsuki Hori, et al.
Investigational New Drugs|June 23, 2021
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 studyYoichi Naito, Yasutoshi Kuboki, Masafumi Ikeda, et al.
Breast Cancer (Tokyo, Japan)|July 30, 2022
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion studyHaruru Kotani, Norikazu Masuda, Toshinari Yamashita, et al.
Cancer Medicine|December 31, 2024
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup AnalysisNobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, et al.
Journal of Pain and Symptom Management|August 27, 2013
Assessment of reasons for referral and activities of hospital palliative care teams using a standard format: a multicenter 1000 case descriptionTomoyo Sasahara, Akiko Watakabe, Etsuko Aruga, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 23, 2008
[Urological oncology emergencies]Natsuki Hori, Masahiro Suzuki
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 9, 2005
[Pain management for cancer patients with critical pathway on computer]Natsuki Hori, Toshiro Konishi
Atherosclerosis|February 8, 2011
Calpain-mediated cleavage negatively regulates the expression level of ABCG1Natsuki Hori, Hisamitsu Hayashi, Yuichi Sugiyama
Nutrients|November 27, 2021
Association of Lifestyle Changes Due to the COVID-19 Pandemic with Nutrient Intake and Physical Activity Levels during Pregnancy in JapanNatsuki Hori, Mie Shiraishi, Rio Harada, et al.
Nutrients|February 11, 2023
Psychosocial Experiences Related to Dietary Behavior of Japanese Lactating Women: A Qualitative StudyKaori Matsuda, Mie Shiraishi, Natsuki Hori, et al.
Investigational New Drugs|June 23, 2021
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 studyYoichi Naito, Yasutoshi Kuboki, Masafumi Ikeda, et al.
Breast Cancer (Tokyo, Japan)|July 30, 2022
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion studyHaruru Kotani, Norikazu Masuda, Toshinari Yamashita, et al.
Cancer Medicine|December 31, 2024
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup AnalysisNobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, et al.
Journal of Pain and Symptom Management|August 27, 2013
Assessment of reasons for referral and activities of hospital palliative care teams using a standard format: a multicenter 1000 case descriptionTomoyo Sasahara, Akiko Watakabe, Etsuko Aruga, et al.
Pageof 1